Seattle Genetics, Inc. (NASDAQ:SGEN) will be hosting a conference call at 4:30 PM eastern time on 29th October 2020, to discuss its 3Q20 financial results with the investment community.
A live webcast with presentations will be available on the Internet by visiting the Company website www.seattlegenetics.com
Earnings Expectation
Seattle Genetics, Inc. is reporting third quarter earnings results on Thursday 29th October 2020, after market close.
The consensus estimates from Thomson Reuters are income of $ 0.50 per share from $ 508.49 million in revenue. For the full year, analysts predict revenues of $ 1502.28 million, while looking forward to loss of $ 0.29 per share.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 1,025.00 million ~ $ 1,100.00 million
Click Here For More Historical Outlooks Of Seattle Genetics, Inc.
Seattle Genetics, Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas. It also conducts various clinical trials to evaluate the combination of ADCETRIS and nivolumab to treat patients with relapsed or refractory, or transplant-ineligible, advanced classical Hodgkin lymphoma; relapsed or refractory B-cell and T-cell non-Hodgkin lymphomas; second-line Hodgkin lymphoma; and relapsed/refractory classical Hodgkin lymphoma, as well as to treat Hodgkin lymphoma in patients with age 60 years or older.
